Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Neurology & Psychiatry
Filter     Order     Display # 
Date Item Title
04 Sep 2008 Naltrexone effective in the treatment of Amphetamine Dependence
03 Sep 2008 Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
03 Sep 2008 Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer's and Huntington's Diseases
03 Sep 2008 Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
03 Sep 2008 Opexa Therapeutics and Myelin Repair Foundation Partner on Novel Multiple Sclerosis Research Program
02 Sep 2008 Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
02 Sep 2008 Anavex Completes Successful Preclinical Studies on Lead Alzheimer's Drug Candidate
01 Sep 2008 Diamyd Medical's NTDDS Technology Effective Against Diabetes Pain
31 Aug 2008 Proximagen Signs $232 Million Licensinf Agreement with Upsher-Smith to Develop PRX1 Programe
28 Aug 2008 Valeant Pharmaceuticals and GlaxoSmithKline Announce Worldwide Collaboration Agreement for Retigabine
27 Aug 2008 FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
27 Aug 2008 Pain Therapeutics and King Pharmaceuticals Develop a New Abuse-Resistant Prescription Pain Medication
26 Aug 2008 ADAGIO Trial Results Show Teva's AZILECT(R) 1 mg Tablets Slow Progression of Parkinson's Disease
25 Aug 2008 Role of pramipexole in key research areas of Parkinson’s disease management discussed at 12th EFNS Congress
25 Aug 2008 Patients Taking Cymbalta® Experienced Reduced Chronic Low Back Pain in New Study
24 Aug 2008 Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
21 Aug 2008 Javelin Presents Successful Pivotal Phase 3 Secondary Clinical Results for Dyloject(TM) at the 12th World Congress on Pain
21 Aug 2008 Boehringer Ingelheim extends research collaboration with Ablynx for Alzheimer's disease
19 Aug 2008 Neurologix Initiates Recruitment for Phase 2 Parkinson's Disease Trial
15 Aug 2008 XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington’s Disease
14 Aug 2008 Bioms Medical Announces Positive Interim Analysis on Phase III Trial of Dirucotide (MBP8298) For Multiple Sclerosis
12 Aug 2008 Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
12 Aug 2008 Pharmacokinetics Study Confirms Therapeutic-Enabling Quantities of Allon's Drugs AL-108 and AL-208 in Human Cerebrospinal Fluid
12 Aug 2008 FDA Accepts REMOXY New Drug Application and Grants Priority Review
11 Aug 2008 RemeGenix Funded by the Alzheimer's Drug Discovery Foundation to Commercialize BRI2 Peptides for Use in Treating Alzheimer's Disease
07 Aug 2008 ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease
07 Aug 2008 IMPAX Reports Positive Results in Phase III Trial with IPX056
06 Aug 2008 Cortex's AMPAKINE Molecule CX717 Has Positive Effects in Opiate-Induced Respiratory Depression in a Phase IIa Clinical Study
05 Aug 2008 Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
04 Aug 2008 Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
03 Aug 2008 Evotec Announces Initiation of Phase I Clinical Trial of VR1 Antagonist under Partnership with Pfizer Inc.
03 Aug 2008 Amgen Licenses Molecule for the Treatment of Chronic and Neuropathic Pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc.
03 Aug 2008 Bioms Medical Completes Patient Recruitment in Phase III U.S. Multiple Sclerosis Trial
31 Jul 2008 New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
31 Jul 2008 Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease
31 Jul 2008 Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008
31 Jul 2008 Ore Pharmaceuticals Acquires Repositioned Clinical-Stage Drug Candidate from Roche
31 Jul 2008 Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease
30 Jul 2008 Synosia Therapeutics Initiates Study of Potential First Drug Therapy for Cocaine Dependence
30 Jul 2008 Elan and Wyeth Present Encouraging Results from Phase 2 Clinical Trial of Bapineuzumab at International Conference on Alzheimer's Disease
30 Jul 2008 TauRx Therapeutics Ltd & University of Aberdeen - New treatment halts progress of Alzheimer's disease
29 Jul 2008 UCB Receives Not-approvable Letter From FDA For Lacosamide For Diabetic Neuropathic Pain
29 Jul 2008 Nutra Pharma Announces Completion of Clinical Study in Adrenomyeloneuropathy (AMN)
29 Jul 2008 Allon Therapeutics presents AL-108 human efficacy data at world’s leading Alzheimer’s disease conference
28 Jul 2008 Eisai Receives Action Letter on Fospropofol Disodium Injection For Sedation in Diagnostic or Therapeutic Procedures
28 Jul 2008 Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
28 Jul 2008 Titan Pharmaceuticals Announces Positive Results from Phase III Clinical Trial of Probuphine for the Treatment of Opioid Addiction
26 Jul 2008 Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
26 Jul 2008 PAION announces dosing of first healthy volunteers in Phase I study with its sedative/anaesthetic CNS 7056
24 Jul 2008 Santhera Receives First Product Approval: Health Canada Approves Catena(r) for Treatment of Friedreich’s Ataxia
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 101 - 150 of 1619

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics